{"resourceType":"ResearchStudy","id":"example-ctgov-study-record","contained":[{"resourceType":"EvidenceVariable","id":"NCT05503693-drug------ap303-50-g","name":"NCT05503693_drug______ap303_50_g","title":"AP303 50 μg","status":"active","description":"AP303 tablet","useContext":[{"code":{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType","code":"interventionType","display":"Intervention Type for ClinicalTrials.gov"},"valueCodeableConcept":{"text":"DRUG"}}]},{"resourceType":"EvidenceVariable","id":"NCT05503693-drug------ap303-150-g","name":"NCT05503693_drug______ap303_150_g","title":"AP303 150 μg","status":"active","description":"AP303 tablet","useContext":[{"code":{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType","code":"interventionType","display":"Intervention Type for ClinicalTrials.gov"},"valueCodeableConcept":{"text":"DRUG"}}]},{"resourceType":"EvidenceVariable","id":"NCT05503693-drug------ap303-300-g","name":"NCT05503693_drug______ap303_300_g","title":"AP303 300 μg","status":"active","description":"AP303 tablet","useContext":[{"code":{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType","code":"interventionType","display":"Intervention Type for ClinicalTrials.gov"},"valueCodeableConcept":{"text":"DRUG"}}]},{"resourceType":"EvidenceVariable","id":"NCT05503693-drug------ap303-600-g","name":"NCT05503693_drug______ap303_600_g","title":"AP303 600 μg","status":"active","description":"AP303 tablet","useContext":[{"code":{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType","code":"interventionType","display":"Intervention Type for ClinicalTrials.gov"},"valueCodeableConcept":{"text":"DRUG"}}]},{"resourceType":"EvidenceVariable","id":"NCT05503693-drug------placebo-50-g","name":"NCT05503693_drug______placebo_50_g","title":"Placebo 50 μg","status":"active","description":"Placebo tablet","useContext":[{"code":{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType","code":"interventionType","display":"Intervention Type for ClinicalTrials.gov"},"valueCodeableConcept":{"text":"DRUG"}}]},{"resourceType":"EvidenceVariable","id":"NCT05503693-drug------placebo-150-g","name":"NCT05503693_drug______placebo_150_g","title":"Placebo 150 μg","status":"active","description":"Placebo tablet","useContext":[{"code":{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType","code":"interventionType","display":"Intervention Type for ClinicalTrials.gov"},"valueCodeableConcept":{"text":"DRUG"}}]},{"resourceType":"EvidenceVariable","id":"NCT05503693-drug------placebo-300-g","name":"NCT05503693_drug______placebo_300_g","title":"Placebo 300 μg","status":"active","description":"Placebo tablet","useContext":[{"code":{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType","code":"interventionType","display":"Intervention Type for ClinicalTrials.gov"},"valueCodeableConcept":{"text":"DRUG"}}]},{"resourceType":"EvidenceVariable","id":"NCT05503693-drug------placebo-600-g","name":"NCT05503693_drug______placebo_600_g","title":"Placebo 600 μg","status":"active","description":"Placebo tablet","useContext":[{"code":{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType","code":"interventionType","display":"Intervention Type for ClinicalTrials.gov"},"valueCodeableConcept":{"text":"DRUG"}}]},{"resourceType":"Group","id":"NCT05503693-comparison-group-0","identifier":[{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-comparison-group-0","assigner":{"display":"Computable Publishing LLC"}}],"title":"NCT05503693 Comparison Group: AP303","status":"active","description":"AP303","useContext":[{"code":{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure","code":"ArmGroupType","display":"Arm Group Type"},"valueCodeableConcept":{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-ArmGroupType","code":"EXPERIMENTAL","display":"Experimental"}]}}],"membership":"conceptual","combinationMethod":"all-of","characteristic":[{"code":{"text":"Exposed to"},"valueReference":{"reference":"#NCT05503693-drug------ap303-50-g","type":"EvidenceVariable","display":"Drug: AP303 50 μg"},"exclude":false},{"code":{"text":"Exposed to"},"valueReference":{"reference":"#NCT05503693-drug------ap303-150-g","type":"EvidenceVariable","display":"Drug: AP303 150 μg"},"exclude":false},{"code":{"text":"Exposed to"},"valueReference":{"reference":"#NCT05503693-drug------ap303-300-g","type":"EvidenceVariable","display":"Drug: AP303 300 μg"},"exclude":false},{"code":{"text":"Exposed to"},"valueReference":{"reference":"#NCT05503693-drug------ap303-600-g","type":"EvidenceVariable","display":"Drug: AP303 600 μg"},"exclude":false}]},{"resourceType":"Group","id":"NCT05503693-comparison-group-1","identifier":[{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-comparison-group-1","assigner":{"display":"Computable Publishing LLC"}}],"title":"NCT05503693 Comparison Group: Placebo","status":"active","description":"Placebo","useContext":[{"code":{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure","code":"ArmGroupType","display":"Arm Group Type"},"valueCodeableConcept":{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-ArmGroupType","code":"PLACEBO_COMPARATOR","display":"Placebo Comparator"}]}}],"membership":"conceptual","combinationMethod":"all-of","characteristic":[{"code":{"text":"Exposed to"},"valueReference":{"reference":"#NCT05503693-drug------placebo-50-g","type":"EvidenceVariable","display":"Drug: Placebo 50 μg"},"exclude":false},{"code":{"text":"Exposed to"},"valueReference":{"reference":"#NCT05503693-drug------placebo-150-g","type":"EvidenceVariable","display":"Drug: Placebo 150 μg"},"exclude":false},{"code":{"text":"Exposed to"},"valueReference":{"reference":"#NCT05503693-drug------placebo-300-g","type":"EvidenceVariable","display":"Drug: Placebo 300 μg"},"exclude":false},{"code":{"text":"Exposed to"},"valueReference":{"reference":"#NCT05503693-drug------placebo-600-g","type":"EvidenceVariable","display":"Drug: Placebo 600 μg"},"exclude":false}]},{"resourceType":"Location","id":"NCT05503693-Location-0","name":"Nucleus Network Pty Ltd","address":{"city":"Melbourne","state":"Victoria","postalCode":"3004","country":"Australia"},"position":{"longitude":144.96332,"latitude":-37.814}}],"url":"https://fevir.net/resources/ResearchStudy/112103","identifier":[{"type":{"text":"FEvIR Object Identifier"},"system":"urn:ietf:rfc:3986","value":"https://fevir.net/FOI/112103","assigner":{"display":"Computable Publishing LLC"}},{"use":"official","system":"https://clinicaltrials.gov","value":"NCT05503693"},{"value":"AP303-PK-01","assigner":{"display":"Alebund Pharmaceuticals"}}],"name":"NCT05503693_FHIR_Transform","title":"A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects","label":[{"type":{"coding":[{"system":"http://hl7.org/fhir/title-type","code":"official","display":"Official title"}]},"value":"A Single-center Randomized Double-blind Placebo-controlled Study to Investigate the Safety Tolerability and PK of SAD and MAD of AP303 Following Oral Administration and the Effect of Food on the PK of AP303 in Healthy Subjects"}],"relatesTo":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/artifact-relationship-type","code":"transforms","display":"Transforms"}]},"targetUri":"https://clinicaltrials.gov/api/v2/studies/NCT05503693?format\u003djson"},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/artifact-relationship-type","code":"transformed-with","display":"Transformed With"}]},"targetAttachment":{"url":"https://fevir.net/resources/Project/29885","title":"Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"}}],"status":"active","purposeType":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-purpose-type","code":"treatment","display":"Treatment Study"}]}],"phase":{"coding":[{"system":"https://fevir.net/sevco","code":"SEVCO:01030","display":"Phase 1 trial"}]},"studyDesign":[{"text":"Design Masking: Quadruple"},{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-WhoMasked","code":"PARTICIPANT","display":"Participant"},{"system":"https://fevir.net/sevco","code":"SEVCO:01060","display":"Blinding of study participants"}]},{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-WhoMasked","code":"CARE_PROVIDER","display":"Care Provider"},{"system":"https://fevir.net/sevco","code":"SEVCO:01061","display":"Blinding of intervention providers"}]},{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-WhoMasked","code":"INVESTIGATOR","display":"Investigator"},{"system":"https://fevir.net/sevco","code":"SEVCO:01063","display":"Blinding of data analysts"}]},{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-WhoMasked","code":"OUTCOMES_ASSESSOR","display":"Outcomes Assessor"},{"system":"https://fevir.net/sevco","code":"SEVCO:01062","display":"Blinding of outcome assessors"}]},{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-DesignAllocation","code":"RANDOMIZED","display":"Randomized"},{"system":"https://fevir.net/sevco","code":"SEVCO:01003","display":"randomized assignment"}]},{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionalAssignment","code":"SEQUENTIAL","display":"Sequential Assignment"},{"system":"https://fevir.net/sevco","code":"SEVCO:01025","display":"Single-arm crossover design"}]},{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-StudyType","code":"INTERVENTIONAL","display":"Interventional"},{"system":"https://fevir.net/sevco","code":"SEVCO:01001","display":"interventional research"}]}],"condition":[{"text":"Healthy Subjects"}],"keyword":[{"text":"Safety, Tolerability, Pharmacokinetics, AP303, Healthy Subjects"}],"descriptionSummary":"This is a single-center, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered AP303 will be assessed in healthy adult subjects.","description":"The study will consist of 2 parts: Part A is a single ascending doses (SAD) phase enrolling a total of 4 cohorts of healthy subjects; Part B is a multiple ascending doses (MAD) phase enrolling 3 cohorts of healthy subjects. One cohort of Part A will receive AP303 under both fasted and fed conditions to investigate the effect of food.","site":[{"reference":"#NCT05503693-Location-0","type":"Location"}],"classifier":[{"text":"Has Results: False"},{"text":"Oversight Classifier: oversightHasDmc True"},{"text":"Oversight Classifier: isFdaRegulatedDrug False"},{"text":"Oversight Classifier: isFdaRegulatedDevice False"}],"associatedParty":[{"name":"Alebund Pharmaceuticals","role":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-party-role","code":"sponsor","display":"Sponsor"}]},"classifier":[{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-AgencyClass","code":"INDUSTRY","display":"INDUSTRY"}]}]},{"name":"Alebund Pty Ltd","role":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-party-role","code":"lead-sponsor","display":"Lead sponsor"}]},"classifier":[{"coding":[{"system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-AgencyClass","code":"INDUSTRY","display":"INDUSTRY"}]}]},{"name":"Sam Francis, Doctor","role":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-party-role","code":"primary-investigator","display":"Principal investigator"}]},"party":{"display":"Nucleus Network"}}],"progressStatus":[{"state":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-status","code":"completed","display":"Completed"}]}},{"state":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-status","code":"overall-study","display":"Overall study"}]},"actual":true,"period":{"start":"2022-12-06","end":"2023-07-21"}}],"recruitment":{"actualNumber":62,"eligibility":{"reference":"Group/112075","type":"Group","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693 Eligibility Criteria","assigner":{"display":"Computable Publishing LLC"}}}},"comparisonGroup":[{"eligibility":{"reference":"#NCT05503693-comparison-group-0","type":"Group","display":"AP303"}},{"eligibility":{"reference":"#NCT05503693-comparison-group-1","type":"Group","display":"Placebo"}}],"objective":[{"outcomeMeasure":[{"name":"Single Dose and Food Effect Safety Outcome Measures","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"Incidence and severity of adverse events (AEs), laboratory, ECG, and vital sign changes","endpoint":{"reference":"EvidenceVariable/112076","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-0","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Multiple Dose Safety Outcome Measures","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"Incidence and severity of AEs, laboratory, ECG, and vital sign changes.","endpoint":{"reference":"EvidenceVariable/112077","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-1","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Cmax after single dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after single dose","endpoint":{"reference":"EvidenceVariable/112078","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-2","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Tmax after single dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after single dose","endpoint":{"reference":"EvidenceVariable/112079","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-3","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"AUC0-last after single dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after single dose","endpoint":{"reference":"EvidenceVariable/112080","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-4","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"AUC0-inf after single dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after single dose","endpoint":{"reference":"EvidenceVariable/112081","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-5","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"t1/2 after single dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after single dose","endpoint":{"reference":"EvidenceVariable/112082","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-6","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"CL/F after single dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after single dose","endpoint":{"reference":"EvidenceVariable/112083","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-7","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Ae and CLR (if warranted) after single dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after single dose","endpoint":{"reference":"EvidenceVariable/112084","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-8","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"V/F after single dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after single dose","endpoint":{"reference":"EvidenceVariable/112085","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-9","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Cmax after multiple dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after multiple dose","endpoint":{"reference":"EvidenceVariable/112086","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-10","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Tmax after multiple dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after multiple dose","endpoint":{"reference":"EvidenceVariable/112087","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-11","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"AUC0-τ after multiple dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after multiple dose","endpoint":{"reference":"EvidenceVariable/112088","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-12","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Cav after multiple dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after multiple dose","endpoint":{"reference":"EvidenceVariable/112089","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-13","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"t1/2 after multiple dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after multiple dose","endpoint":{"reference":"EvidenceVariable/112090","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-14","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Rac after multiple dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after multiple dose","endpoint":{"reference":"EvidenceVariable/112091","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-15","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Ae and CLR (if warranted) after multiple dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after multiple dose","endpoint":{"reference":"EvidenceVariable/112092","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-16","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"V/F after multiple dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after multiple dose","endpoint":{"reference":"EvidenceVariable/112093","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-17","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Ctrough after multiple dose","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"primary","display":"Primary"}]},"description":"PK characteristics after multiple dose","endpoint":{"reference":"EvidenceVariable/112094","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-primaryOutcome-18","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Effect of Food on the single dose Cmax","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"secondary","display":"Secondary"}]},"description":"Effect of food on the single dose PK","endpoint":{"reference":"EvidenceVariable/112095","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-secondaryOutcome-0","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Effect of Food on the single dose Tmax","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"secondary","display":"Secondary"}]},"description":"Effect of food on the single dose PK","endpoint":{"reference":"EvidenceVariable/112096","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-secondaryOutcome-1","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Effect of Food on the single dose AUC0-last","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"secondary","display":"Secondary"}]},"description":"Effect of food on the single dose PK","endpoint":{"reference":"EvidenceVariable/112097","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-secondaryOutcome-2","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Effect of Food on the single dose AUC0-inf","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"secondary","display":"Secondary"}]},"description":"Effect of food on the single dose PK","endpoint":{"reference":"EvidenceVariable/112098","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-secondaryOutcome-3","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Effect of Food on the single dose t1/2","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"secondary","display":"Secondary"}]},"description":"Effect of food on the single dose PK","endpoint":{"reference":"EvidenceVariable/112099","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-secondaryOutcome-4","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Effect of Food on the single dose CL/F","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"secondary","display":"Secondary"}]},"description":"Effect of food on the single dose PK","endpoint":{"reference":"EvidenceVariable/112100","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-secondaryOutcome-5","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Effect of Food on the single dose Ae and CLR (if warranted)","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"secondary","display":"Secondary"}]},"description":"Effect of food on the single dose PK","endpoint":{"reference":"EvidenceVariable/112101","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-secondaryOutcome-6","assigner":{"display":"Computable Publishing LLC"}}}},{"name":"Effect of Food on the single dose V/F","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type","code":"secondary","display":"Secondary"}]},"description":"Effect of food on the single dose PK","endpoint":{"reference":"EvidenceVariable/112102","type":"EvidenceVariable","identifier":{"type":{"text":"FEvIR Linking Identifier"},"system":"https://fevir.net/FLI","value":"NCT05503693-secondaryOutcome-7","assigner":{"display":"Computable Publishing LLC"}}}}]}]}